Patrick Nosker News Today

The first year of the covid-19 pandemic fueled a frenzy for biotechnology stocks. Now, with vaccines in millions of arms and the omicron variant on the wane, there are signs investors are ready to move on.

While an appetite for the shares of vaccine makers and drug companies remain, inflows into health care funds have slowed to more modest figures.